Compare HTOO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTOO | APVO |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | Ireland | United States |
| Employees | 131 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.3M |
| IPO Year | N/A | 2023 |
| Metric | HTOO | APVO |
|---|---|---|
| Price | $2.72 | $4.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.0K | ★ 27.0K |
| Earning Date | 02-28-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | $4,832.46 | N/A |
| Revenue Next Year | $81.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.50 |
| 52 Week High | $12.63 | $10.70 |
| Indicator | HTOO | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 48.73 |
| Support Level | $2.53 | $4.29 |
| Resistance Level | $3.60 | $5.59 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 0.00 | 29.02 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats. It earns majority revenue from UAE.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.